Kevan Herold, MD
Endocrinology, Diabetes & Metabolism · New Haven, CTNPI 1083709463
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Sanofi-aventis U.S. LLC accounts for 78.5% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $96,314, more than ten times the $3,980 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 89 payments — averaging $2927.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$204K
- Sanofi$25K
- Boehringer Ingelheim$6K
- Merck$5K
- Sanofi US Services Inc.$4K
- Vertex$4K
- plus $12K from 4 others
Across 11 payments — averaging $4422.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$28K
- Pfizer$21K
What the payments were for
- Consulting fees$120,75246%
- Speaking & faculty fees$84,12632%
- Travel & lodging$53,58121%
- Food & beverage$2,0841%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 65 | $204,489 |
| Sanofi | 8 | $24,703 |
| Boehringer Ingelheim | 4 | $6,379 |
| Merck | 1 | $5,100 |
| Sanofi US Services Inc. | 2 | $4,122 |
| Vertex | 3 | $4,034 |
| Pfizer | 2 | $3,980 |
| Biogen | 1 | $3,675 |
| Novo Nordisk AS | 2 | $3,543 |
| GSK | 1 | $518 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TOUJEO$71,794
- TZIELD$45,474
- SOLIQUA 100/33$3,545
How this compares
$260,543 in reported general payments places this provider in the 95th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
See all endocrinology, diabetes & metabolism providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in New Haven
- Ania JastreboffNew Haven$536K
- Silvio InzucchiNew Haven$461K
- Philip GoldbergNew Haven$324K
- Gerald ShulmanNew Haven$194K
- Karl InsognaNew Haven$68K
- Clemens BergwitzNew Haven$31K
- Richard KibbeyNew Haven$18K
- Peter TebbenNew Haven$17K
- Surani FernandoNew Haven$13K
- Irina RosewaterNew Haven$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.